Senegal

Senegal

Hepatitis B

Download HBV data

Prevalence of chronic HBV (HBsAg+)

National
Download
Value (%) Year Type Source
6.44 (5.31 - 7.63) 2019 Modelled IHME
7.07 (5.89 - 8.17) 2018 Modelled IHME
7.35 (6.13 - 8.63) 2017 Modelled IHME
7.34 (6.07 - 8.65) 2016 Modelled IHME
7.33 (5.84 - 8.83) 2015 Modelled IHME
7.44 (5.95 - 8.94) 2014 Modelled IHME
7.68 (6.17 - 9.23) 2013 Modelled IHME
8 (6.42 - 9.62) 2012 Modelled IHME
8.33 (6.71 - 10.03) 2011 Modelled IHME
8.6 (6.93 - 10.35) 2010 Modelled IHME
8.8 (7.16 - 10.48) 2009 Modelled IHME
8.99 (7.33 - 10.66) 2008 Modelled IHME
9.17 (7.49 - 10.86) 2007 Modelled IHME
9.36 (7.66 - 11.12) 2006 Modelled IHME
9.56 (7.83 - 11.48) 2005 Modelled IHME
9.83 (7.99 - 11.67) 2004 Modelled IHME
10.14 (8.15 - 12.10) 2003 Modelled IHME
10.46 (8.32 - 12.67) 2002 Modelled IHME
10.72 (8.47 - 13.19) 2001 Modelled IHME
10.9 (8.59 - 13.39) 2000 Modelled IHME
11 (8.74 - 13.34) 1999 Modelled IHME
11.09 (8.92 - 13.33) 1998 Modelled IHME
11.16 (8.98 - 13.27) 1997 Modelled IHME
11.22 (9.06 - 13.29) 1996 Modelled IHME
11.25 (9.08 - 13.43) 1995 Modelled IHME
11.26 (9.11 - 13.29) 1994 Modelled IHME
11.27 (9.14 - 13.32) 1993 Modelled IHME
11.27 (9.16 - 13.26) 1992 Modelled IHME
11.26 (9.11 - 13.30) 1991 Modelled IHME
11.23 (9.12 - 13.34) 1990 Modelled IHME
8.18 (6.71 - 9.99) 2015 Modelled WHO
Showing out of
Show more
Children under-5 years
Download
Value (%) Year Type Source
0.97 (0.70 - 1.21) 2019 Modelled IHME
1.08 (0.81 - 1.36) 2018 Modelled IHME
1.15 (0.85 - 1.52) 2017 Modelled IHME
1.19 (0.88 - 1.56) 2016 Modelled IHME
1.22 (0.87 - 1.62) 2015 Modelled IHME
1.28 (0.92 - 1.67) 2014 Modelled IHME
1.35 (1 - 1.74) 2013 Modelled IHME
1.43 (1.05 - 1.84) 2012 Modelled IHME
1.51 (1.11 - 1.93) 2011 Modelled IHME
1.6 (1.17 - 2.05) 2010 Modelled IHME
1.68 (1.24 - 2.14) 2009 Modelled IHME
1.75 (1.31 - 2.23) 2008 Modelled IHME
1.84 (1.36 - 2.35) 2007 Modelled IHME
1.95 (1.44 - 2.51) 2006 Modelled IHME
2.11 (1.56 - 2.76) 2005 Modelled IHME
2.84 (2.14 - 3.69) 2004 Modelled IHME
4.32 (3.30 - 5.55) 2003 Modelled IHME
6.04 (4.63 - 7.75) 2002 Modelled IHME
7.52 (5.73 - 9.69) 2001 Modelled IHME
8.25 (6.19 - 10.77) 2000 Modelled IHME
8.43 (6.27 - 10.88) 1999 Modelled IHME
8.57 (6.37 - 10.92) 1998 Modelled IHME
8.68 (6.42 - 11.07) 1997 Modelled IHME
8.75 (6.41 - 11.31) 1996 Modelled IHME
8.77 (6.35 - 11.51) 1995 Modelled IHME
8.77 (6.40 - 11.38) 1994 Modelled IHME
8.75 (6.45 - 11.26) 1993 Modelled IHME
8.7 (6.42 - 11.19) 1992 Modelled IHME
8.63 (6.47 - 11.14) 1991 Modelled IHME
8.53 (6.42 - 11.08) 1990 Modelled IHME
3.48 (2.43 - 4.84) 2015 Modelled WHO
Showing out of
Show more

Percent of liver cancer deaths attributable to HBV

National
Download
Value (%) Year Type Source
57 (49 - 65) 2019 Modelled IHME
57 (49 - 65) 2018 Modelled IHME
57 (49 - 64) 2017 Modelled IHME
57 (49 - 64) 2016 Modelled IHME
57 (49 - 64) 2015 Modelled IHME
57 (50 - 64) 2014 Modelled IHME
58 (50 - 65) 2013 Modelled IHME
58 (50 - 65) 2012 Modelled IHME
58 (51 - 66) 2011 Modelled IHME
58 (51 - 66) 2010 Modelled IHME
59 (51 - 66) 2009 Modelled IHME
58 (51 - 66) 2008 Modelled IHME
58 (51 - 65) 2007 Modelled IHME
58 (51 - 65) 2006 Modelled IHME
58 (51 - 65) 2005 Modelled IHME
58 (51 - 65) 2004 Modelled IHME
59 (52 - 66) 2003 Modelled IHME
59 (52 - 66) 2002 Modelled IHME
59 (52 - 66) 2001 Modelled IHME
59 (52 - 66) 2000 Modelled IHME
59 (52 - 67) 1999 Modelled IHME
59 (52 - 67) 1998 Modelled IHME
60 (52 - 67) 1997 Modelled IHME
60 (53 - 67) 1996 Modelled IHME
60 (53 - 67) 1995 Modelled IHME
60 (53 - 66) 1994 Modelled IHME
59 (53 - 66) 1993 Modelled IHME
59 (52 - 66) 1992 Modelled IHME
59 (52 - 66) 1991 Modelled IHME
58 (51 - 65) 1990 Modelled IHME
Showing out of
Show more
Technical notes

Coverage of HepB birth dose

Newborns
Download
Value (%) Year Type Source
63 2018 Survey/reported WHO/UNICEF
72 2017 Survey/reported WHO/UNICEF
58 2016 Survey/reported WHO/UNICEF
Showing out of
Show more
Technical notes

Coverage of 3-dose hepatitis B vaccine

Infants
Download
Value (%) Year Type Source
82 2018 Survey/reported WHO/UNICEF
91 2017 Survey/reported WHO/UNICEF
93 2016 Survey/reported WHO/UNICEF
89 2015 Survey/reported WHO/UNICEF
89 2014 Survey/reported WHO/UNICEF
92 2013 Survey/reported WHO/UNICEF
91 2012 Survey/reported WHO/UNICEF
92 2011 Survey/reported WHO/UNICEF
89 2010 Survey/reported WHO/UNICEF
86 2009 Survey/reported WHO/UNICEF
88 2008 Survey/reported WHO/UNICEF
94 2007 Survey/reported WHO/UNICEF
89 2006 Survey/reported WHO/UNICEF
84 2005 Survey/reported WHO/UNICEF
54 2004 Survey/reported WHO/UNICEF
Showing out of
Show more
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HBV testing policy
No policy
HepB birth dose policy
Yes
Year of birth dose introduction
2016
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
No policy
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)

Hepatitis C

Download HCV data

Prevalence of chronic HCV (RNA+/cAg)

National
Download
Value (%) Year Type Source
1.57 (1.26 - 1.96) 2019 Modelled IHME
1.58 (1.27 - 1.96) 2018 Modelled IHME
1.58 (1.26 - 1.96) 2017 Modelled IHME
1.58 (1.27 - 1.98) 2016 Modelled IHME
1.58 (1.27 - 1.98) 2015 Modelled IHME
1.58 (1.28 - 1.97) 2014 Modelled IHME
1.6 (1.28 - 1.99) 2013 Modelled IHME
1.61 (1.30 - 2) 2012 Modelled IHME
1.62 (1.31 - 2.02) 2011 Modelled IHME
1.63 (1.32 - 2.03) 2010 Modelled IHME
1.64 (1.33 - 2.04) 2009 Modelled IHME
1.65 (1.33 - 2.06) 2008 Modelled IHME
1.65 (1.33 - 2.07) 2007 Modelled IHME
1.66 (1.34 - 2.08) 2006 Modelled IHME
1.67 (1.35 - 2.10) 2005 Modelled IHME
1.68 (1.36 - 2.12) 2004 Modelled IHME
1.7 (1.37 - 2.14) 2003 Modelled IHME
1.71 (1.38 - 2.16) 2002 Modelled IHME
1.73 (1.39 - 2.18) 2001 Modelled IHME
1.74 (1.40 - 2.19) 2000 Modelled IHME
1.75 (1.40 - 2.20) 1999 Modelled IHME
1.76 (1.41 - 2.19) 1998 Modelled IHME
1.76 (1.42 - 2.20) 1997 Modelled IHME
1.77 (1.43 - 2.21) 1996 Modelled IHME
1.77 (1.42 - 2.20) 1995 Modelled IHME
1.75 (1.41 - 2.17) 1994 Modelled IHME
1.71 (1.39 - 2.11) 1993 Modelled IHME
1.65 (1.34 - 2.01) 1992 Modelled IHME
1.57 (1.28 - 1.91) 1991 Modelled IHME
1.48 (1.22 - 1.80) 1990 Modelled IHME
Showing out of
Show more

Prevalence of anti-HCV

People who inject drugs (PWID)
Download
Value (%) Year Type Source
39.3 (31.10 - 47.90) 2011 Survey/reported Lepretre A et al, 2015

Percent of liver cancer deaths attributable to HCV

National
Download
Value (%) Year Type Source
9 (6 - 13) 2019 Modelled IHME
9 (6 - 13) 2018 Modelled IHME
9 (6 - 13) 2017 Modelled IHME
9 (6 - 13) 2016 Modelled IHME
9 (6 - 13) 2015 Modelled IHME
9 (6 - 13) 2014 Modelled IHME
9 (6 - 13) 2013 Modelled IHME
9 (6 - 13) 2012 Modelled IHME
9 (6 - 13) 2011 Modelled IHME
9 (6 - 13) 2010 Modelled IHME
9 (6 - 12) 2009 Modelled IHME
9 (6 - 12) 2008 Modelled IHME
9 (6 - 12) 2007 Modelled IHME
9 (6 - 12) 2006 Modelled IHME
9 (5 - 12) 2005 Modelled IHME
8 (5 - 12) 2004 Modelled IHME
8 (5 - 12) 2003 Modelled IHME
8 (5 - 12) 2002 Modelled IHME
8 (5 - 12) 2001 Modelled IHME
8 (5 - 12) 2000 Modelled IHME
8 (5 - 12) 1999 Modelled IHME
8 (5 - 12) 1998 Modelled IHME
8 (5 - 12) 1997 Modelled IHME
8 (5 - 12) 1996 Modelled IHME
8 (5 - 12) 1995 Modelled IHME
8 (5 - 12) 1994 Modelled IHME
8 (5 - 12) 1993 Modelled IHME
8 (5 - 12) 1992 Modelled IHME
8 (5 - 12) 1991 Modelled IHME
8 (5 - 12) 1990 Modelled IHME
Showing out of
Show more
Technical notes
HBV National Action Plan
HBV elimination goal
Year of HBV elimination goal
2030
HBV testing policy
No policy
HepB birth dose policy
Yes
Year of birth dose introduction
2016
Eligible for HBV generic medicines
HCV National Action Plan
HCV elimination goal
Year of HCV elimination goal
2030
HCV testing policy
No policy
Eligible for HCV generic medicines
At least one needle-syringe exchange program (NSP) operational
Yes
At least one opioid substitution therapy (OST) program operational
Yes
NSP in at least one prison
No
OST in at least one prison
No
% of substance use disorder facilities offering hepatitis testing
Few (1-10%)
% of substance use disorder facilities offering hepatitis treatment
Few (1-10%)

Overview

HBV elimination goal
Year of goal
2030
HCV elimination goal
Year of goal
2030

Prevalence (national)

Modelled

HBV (HBsAg+)
6.44 (%)
2019
(5.31 - 7.63(%))
IHME
HCV (RNA/cAg+)
1.57 (%)
2019
(1.26 - 1.96(%))
IHME

Survey/surveillance

No data available
No data available

Hepatitis related deaths (national)

Modelled

HBV
1,190
2019
(800 - 1,672)
IHME

Survey/surveillance

No data available
HBV chart

Modelled

HCV
169
2019
(109 - 251)
IHME

Survey/surveillance

No data available
HCV chart

Prevalence < 5

HBV
0.97 (%)
2019, latest modelled
(0.70 - 1.21(%))
IHME

Prevalence PWID

HCV
39.30 (%)
2011, survey/surveillance
(31.10 - 47.90(%))
Lepretre A et al, 2015

Birth dose vaccination coverage (national)

Survey/surveillance

HBV
63 (%)
2018
WHO/UNICEF

No. of syringes/PWID/year

Survey/surveillance

No data available
Eligible for HBV generic medicines
Eligible for HCV generic medicines